Results 271 to 280 of about 184,433 (313)

Immune Checkpoint Inhibitors in the Treatment of Advanced Melanoma in Older Patients: An Overview of Published Data. [PDF]

Cancers (Basel)
Lens M, Schachter J.
europepmc   +1 more source

Cardiovascular disease incidence and cancer risk in two large European prospective cohorts

International Journal of Cancer, EarlyView.
What's New? Cardiovascular disease (CVD) and cancer share risk factors and biological mechanisms, raising questions about potential associations between the two, particularly regarding CVD duration and cancer onset. Whether CVD influences subsequent cancer risk, however, remains inconclusive.
Emma Fontvieille, Vivian Viallon, Laia Peruchet‐Noray, Quan Gan, N. Charlotte Onland‐Moret, Yvonne Koop, Anne Tjønneland, Nicola Patricia Bondonno, Verena Katzke, Rudolf Kaaks, Matthias B. Schulze, Catarina Schiborn, Calogero Saieva, Vittorio Simeon, Claudia Agnoli, Rosario Tumino, Fulvio Ricceri, Leila Luján‐Barroso, Maria‐José Sánchez, Conchi Moreno‐Iribas, Konstantinos K. Tsilidis, Marc J. Gunter, Adam Butterworth, Elio Riboli, Heinz Freisling, Pietro Ferrari   +25 more
wiley   +1 more source

Efficacy of nivolumab plus relatlimab versus BRAF/MEK inhibitors for first-line treatment of BRAF-mutant advanced melanoma: A matching-adjusted indirect comparison. [PDF]

BMJ Oncol
Miller DM, Smithy JW, Palaia J, Patel D, Salvatore A, D'Adamo D, Mattera M, Zhou ZY, Garcia-Horton V, Tarhini AA.   +9 more
europepmc   +1 more source

Body composition and checkpoint inhibitor treatment outcomes in advanced melanoma: a multicenter cohort study. [PDF]

J Natl Cancer Inst
Schuiveling M, Ter Maat LS, Van Duin IAJ, Verheijden RJ, Troenokarso MF, Moeskops P, Verhoeff JJC, Elias SG, van Amsterdam WAC, Burgers F, Van den Berkmortel FWPJ, Boers-Sonderen MJ, Boomsma MF, De Groot JW, Haanen JBAG, Hospers GAP, Piersma D, Vreugdenhil G, Westgeest HM, Kapiteijn E, Labots M, Veldhuis WB, Van Diest PJ, De Jong PA, Pluim JPW, Leiner T, Veta M, Suijkerbuijk KPM.   +27 more
europepmc   +1 more source

Advanced Melanoma Management: A Case Report of Pembrolizumab Use in a Haemodialysis Patient. [PDF]

Cureus
Teixeira C, Costa R, Silva M, Ribeiro MJ, Sousa I.   +4 more
europepmc   +1 more source

Topical and Intralesional Treatments for Skin Metastases and Locoregionally Advanced Melanoma. [PDF]

Cancers (Basel)
Criado-Otero M, Navedo-de Las Heras M, Samaniego-González E.   +2 more
europepmc   +1 more source

Development of a Decision Model to Estimate the Outcomes of Treatment Sequences in Advanced Melanoma. [PDF]

Med Decis Making
de Groot S, Blommestein HM, Leeneman B, Uyl-de Groot CA, Haanen JBAG, Wouters MWJM, Aarts MJB, van den Berkmortel FWPJ, Blokx WAM, Boers-Sonderen MJ, van den Eertwegh AJM, de Groot JWB, Hospers GAP, Kapiteijn E, van Not OJ, van der Veldt AAM, Suijkerbuijk KPM, van Baal PHM.   +17 more
europepmc   +1 more source

Pembrolizumab and all-trans retinoic acid combination treatment of advanced melanoma: long-term survival update. [PDF]

Ther Adv Med Oncol
Borgers JSW, Medina TM, Robinson WA, Couts KL, Katsnelson EN, Muckle CM, Davilla E, Patel SP, Gao D, Tobin RP, McCarter MD.   +10 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Biochemotherapy for advanced melanoma

Seminars in Oncology, 2002
The outcome of chemotherapy for patients with stage IV melanoma is unsatisfactory, since durable responses are rarely achieved. More experimental treatments, such as vaccine approaches, antibody treatments, and gene therapy are being developed and are of high scientific interest; however, their efficacy in advanced melanoma patients has so far been ...
Ulrich, Keilholz, Martin E, Gore
openaire   +4 more sources

THERAPEUTIC ADVANCES IN MELANOMA

Dermatologic Clinics, 2000
Therapy for melanoma continues to evolve, and with the expanding work in the basic pathophysiology, the continued development of biologic modifiers is expected. With new treatment regimens, the rate of remissions is improving for patients with metastatic disease.
J M, Pitts, M E, Maloney
openaire   +2 more sources